U.S. Construction Stock News

NYSE:CSTM
NYSE:CSTMMetals and Mining

Constellium (CSTM) Stock May Be 4% Undervalued On Raised 2026 Outlook

Constellium stock has more than doubled over the past year, yet current valuation checks suggest it now trades close to its estimated intrinsic value rather than at a clear bargain or premium. Constellium has returned 107.2% over the past year, which puts the recent share price performance front and center for anyone thinking about the current valuation. Record profitability and cash generation can support the case for the current share price, while uncertainty around demand in aerospace and...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Will Zimmer Biomet’s Upgraded 2026 Guidance and Buyback Shift Zimmer Biomet Holdings’ (ZBH) Narrative

Zimmer Biomet Holdings, Inc. reported past second-quarter 2026 results with sales of US$2,177 million and net income of US$198.3 million, and completed a US$496.84 million share repurchase of 5,534,990 shares, or 2.85% of its outstanding stock under its February 2026 buyback program. Management also raised full-year guidance on the back of stronger hip and technology segment performance, highlighting momentum from new products and ongoing U.S. sales force transformation. Now we’ll examine...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

How Could Applied Materials (AMAT) Gain From Its New AI Chip Research Alliance?

Applied Materials (NasdaqGS:AMAT) announced that the University of California, Berkeley is joining its EPIC Center in Silicon Valley as a research collaborator. The alliance focuses on accelerating commercialization of advanced semiconductor materials and process technologies that support AI computing. UC Berkeley researchers gain access to industry scale chipmaking tools, aimed at shortening the path from lab research to high volume manufacturing. The collaboration is also designed to train...
NasdaqCM:NKTR
NasdaqCM:NKTRPharmaceuticals

Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up?

Nektar Therapeutics (NKTR) has drawn investor attention after its stock closed at $76.03, with sizeable moves over the past month and past 3 months prompting a closer look at the biopharmaceutical company. See our latest analysis for Nektar Therapeutics. Over the past year, Nektar Therapeutics has seen strong momentum, with a year-to-date share price return of 75.1% and a 1-year total shareholder return of 195.61%. However, the 5-year total shareholder return remains significantly negative,...
NasdaqGS:ISRG
NasdaqGS:ISRGMedical Equipment

Intuitive Surgical (ISRG) Is Facing Fresh Competition In U.S. Surgical Robotics

Intuitive Surgical (NasdaqGS: ISRG) faces new U.S. competition after Johnson & Johnson received FDA authorization for its Ottava robotic surgical system. Ottava is positioned as a space saving robotic platform that could widen the market for hospitals and surgical centers considering robotic surgery. Johnson & Johnson plans to pair Ottava with its existing surgical tools and devices, creating a fresh challenge to Intuitive Surgical's installed base and recurring revenue streams. Consider...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

AST SpaceMobile (ASTS) Stock Looks Fully Valued After Its Huge Run

AST SpaceMobile stock is coming off a very strong three year run, yet the current valuation checks lean mixed rather than clearly cheap or clearly expensive. After that kind of performance, the question for investors is how much of the company’s satellite to smartphone opportunity is already reflected in the price. AST SpaceMobile has delivered a very large 3 year return of about 19x, which puts extra focus on whether the current share price still leaves room for further value...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

BioNTech (BNTX) Names Guido Oelkers As Incoming Chief Executive Officer

BioNTech (NasdaqGS:BNTX) has appointed Guido Oelkers, Ph.D., as its incoming Chief Executive Officer, succeeding founder Prof. Ugur Sahin. Oelkers brings global leadership experience across public and private biopharmaceutical companies, with a focus on oncology, immunology and business scaling. The transition marks a shift from a founder-led structure to an external CEO. This change can influence BioNTech's future direction and execution. Consider broadening your watchlist to include other...
NYSE:GNL
NYSE:GNLREITs

Global Net Lease (GNL) Reports Q2 Results And Buybacks, Is The Undervalued Case Still Intact?

Global Net Lease (GNL) just reported second quarter 2026 results alongside an update on its share repurchase program, giving investors fresh detail on operating performance, capital allocation, and how management is reshaping the real estate portfolio. See our latest analysis for Global Net Lease. Global Net Lease shares trade at $8.99 and the stock has risen 4.29% on a 7 day share price return and 1.93% on a year to date share price return, while the 1 year total shareholder return of 27.88%...
NYSE:LOB
NYSE:LOBBanks

Live Oak Bancshares (LOB) On Its Q2 Beat And The Valuation Case Today

Q2 beat and investor reaction Live Oak Bancshares (LOB) recently reported Q2 results that exceeded analyst estimates for net interest income and earnings per share. The stock has gained 3.8% since the release, highlighting how quickly investors responded to the update. See our latest analysis for Live Oak Bancshares. Over a longer window, Live Oak Bancshares has paired its Q2 beat with an 18.15% 90-day share price return and a 23.19% year-to-date share price return. The 1-year total...
NYSE:WMK
NYSE:WMKConsumer Retailing

Is Weis Markets (WMK) A Bargain As Mixed Earnings Cloud Its Valuation?

Weis Markets earnings snapshot after mixed quarter Weis Markets (WMK) reported second quarter and first half 2026 results, with sales and revenue above last year while quarterly net income and earnings per share from continuing operations declined. Over the six month period to June 27, 2026, the company reported higher sales, revenue and net income compared with the prior year, setting a different tone from the softer profit picture in the latest quarter. See our latest analysis for Weis...